Peter Nell, Mammoth Biosciences CBO
Jennifer Doudna spinout inks a Mammoth CRISPR deal with Vertex worth nearly $700M
When a company gets its start in gene editing pioneer Jennifer Doudna’s lab, it’s bound to make headlines. But three years in, the fanfare still …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
